Theravance Biopharma (TBPH) Depreciation & Amortization (CF) (2013 - 2026)
Theravance Biopharma (TBPH) reported Depreciation & Amortization (CF) of $381000.0 for Q1 2026, down 7.75% year-over-year from $413000.0 in Q1 2025, and down 4.51% quarter-over-quarter from $399000.0 in Q4 2025.
Theravance Biopharma (TBPH) Depreciation & Amortization (CF) (2013 - 2026) Analysis & Trends
Theravance Biopharma (TBPH) has 14 years of Depreciation & Amortization (CF) data on file, last reported at $381000.0 in Q1 2026.
- Depreciation & Amortization (CF) for Q1 2026 came in at $381000.0, down 7.75% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.6 million (down 5.74% YoY), and the FY2025 annual result was $1.6 million, down 4.91% from the prior year.
- Depreciation & Amortization (CF) retreated to $381000.0 in Q1 2026 per TBPH's latest filing, from $399000.0 in the prior quarter.
- Over five years, Depreciation & Amortization (CF) peaked at $1.1 million in Q3 2022 and troughed at $381000.0 in Q1 2026.
- A 5-year average of $554941.2 and a median of $429000.0 in 2024 frame the typical range for Depreciation & Amortization (CF).
- The sharpest annual moves came in 2022 and 2023: Depreciation & Amortization (CF) soared 162.55% in 2022, then slumped 61.01% in 2023.
- A 5-year view of Depreciation & Amortization (CF) shows it stood at $659000.0 in 2022, then plunged by 40.52% to $392000.0 in 2023, then advanced by 7.65% to $422000.0 in 2024, then slipped by 5.45% to $399000.0 in 2025, then slipped by 4.51% to $381000.0 in 2026.
- Business Quant data shows TBPH's Depreciation & Amortization (CF) at $381000.0 in Q1 2026, $399000.0 in Q4 2025, and $405000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Dep. & Amort. (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 719,706.53 Bn | 719,706.50 Bn | - | 1,395.22 |
| 2 | Belite Bio | 55,800.00 Bn | 55,800.00 Bn | - | - |
| 3 | Quantum Biopharma | 18,182.30 Bn | 18,182.29 Bn | - | - |
| 4 | Legend Biotech | 3,154.00 Bn | 3,153.71 Bn | 242.10 Mn | - |
| 5 | Akari Therapeutics | 1,844.30 Bn | 1,844.29 Bn | - | - |
| 6 | Evaxion A | 1,567.96 Bn | 1,567.94 Bn | - | - |
| 7 | Psyence Biomedical | 251.43 Bn | 251.42 Bn | - | -1,330.00 |
| 8 | Vertex Pharmaceuticals | 112.56 Bn | 105.31 Bn | 2.59 Bn | 55.90 Mn |
| 9 | Abivax | 94.37 Bn | 94.37 Bn | - | 429,663.65 |
| 10 | Theravance Biopharma | 835.85 Mn | 441.18 Mn | - | 381,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 381,000.00 |
| Mar 31, 2026 | 381,000.00 |
| Dec 31, 2025 | 399,000.00 |
| Dec 31, 2025 | 399,000.00 |
| Sep 30, 2025 | 405,000.00 |
| Sep 30, 2025 | 405,000.00 |
| Jun 30, 2025 | 409,000.00 |
| Jun 30, 2025 | 409,000.00 |
| Mar 31, 2025 | 413,000.00 |
| Mar 31, 2025 | 413,000.00 |
| Dec 31, 2024 | 422,000.00 |
| Dec 31, 2024 | 422,000.00 |
| Sep 30, 2024 | 429,000.00 |
| Sep 30, 2024 | 429,000.00 |
| Jun 30, 2024 | 427,000.00 |
| Jun 30, 2024 | 427,000.00 |
| Mar 31, 2024 | 432,000.00 |
| Mar 31, 2024 | 432,000.00 |
| Dec 31, 2023 | 392,000.00 |
| Dec 31, 2023 | 392,000.00 |